Date: 2016-09-26
Type of information: Nomination
Compound:
Company: Swedish Orphan Biovitrum - SOBI (Sweden)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 26, 2016, Swedish Orphan Biovitrum (Sobi™) announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development. Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the Research and Development organisation responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity. Milan will lead Sobi’s R&D efforts from post-proof of concept to late life cycle development, focusing on advancing and expanding Sobi’s early and mid-stage pipeline under a unified innovation strategy. Milan will join Sobi on 1 November 2016.
Financial terms:
Latest news:
